Alzheimer’s disease (AD) is a brain disorder that slowly destroys memory and thinking abilities.
The commonly reported early symptoms are memory loss, unpredictable behavior, language problems, confusion, etc.
The drugs available for treating AD can give temporary relief from worsening of symptoms, but they do not stop AD from progressing.
The biggest challenges for the pharmaceutical industries and their researchers are the high cost of research, lack of recruitment of participants in the clinical trials, and the inability to detect AD early.
Despite this, more than 400 clinical trials and billions of dollars are being spent by the pharmaceutical industries to treat this disease.
Earlier diagnosis can also help to improve the terrible financial burden of AD.